ProQR Therapeutics: Funding, Investors & Team (Oct 2026)
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
ProQR Therapeutics has raised $59.2M across 1 funding round on record, the most recent an undisclosed round of $59.2M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ProQR Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
ProQR Therapeutics Funding Rounds
ProQR Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
ProQR Therapeutics Funding Compared to Other Biotechnology Startups
ProQR Therapeutics' latest round of $59.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ProQR Therapeutics in Biotechnology and Leiden
Companies Similar to ProQR Therapeutics
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene…
Vertoro transforms woody and agricultural residues into a wide range of bio-based chemicals, materials, and…
Vivici is a B2B ingredients firm that provides nutritious and sustainable animal-free dairy proteins…
New Dawn Bio is a biotechnology research firm that specializes in wood production.
Triple Bio is a biotech startup focused on improving productivity and sustainability in dairy and beef…
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and…
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the…
Detact holds the patent for a new, innovative, real-time, bacterial detection system that enables hospital…
BioLinker is a creation of manufactured science, protein blend packs, and protein.
WhiteLab Genomics develops digital tools that help gene and cell therapy companies develop cheaper drugs…
Tydra Labs is a biotechnology company that transforms crustacean shell waste into chitin and bio-products.
ProQR Therapeutics Funding FAQs
What does ProQR Therapeutics do?
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
How much funding has ProQR Therapeutics raised?
ProQR Therapeutics has raised $59.2M across 1 round on record. The most recent is an undisclosed round of $59.2M announced in Jun 2026.
When did ProQR Therapeutics last raise funding?
ProQR Therapeutics' most recent funding round on record is an undisclosed round of $59.2M, announced in Jun 2026.
Who founded ProQR Therapeutics?
FundedIQ lists Daniel De (Founder) at ProQR Therapeutics.
Where is ProQR Therapeutics headquartered?
ProQR Therapeutics is based in Leiden, Zuid-Holland, The Netherlands.
How many employees does ProQR Therapeutics have?
ProQR Therapeutics is in the 101-250 employee band.
How does ProQR Therapeutics' funding compare to other Biotechnology startups?
ProQR Therapeutics' latest round of $59.2M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ProQR Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ProQR Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.